Drug intelligence / Profile preview

compound 121564

Development stage: Unknown
Lead developer: American University of Beirut Medical Center
Modality: Small Molecules
Administration: Intravenous

Overview

Compound 121564 is a small molecule antineoplastic drug under development as a neoadjuvant therapy for early-stage non-small cell lung cancer. It is being developed by the American University of Beirut Medical Center in collaboration with Merck KGaA. The precise mechanism of action has not been defined or disclosed publicly. Compound 121564 is classified as a new molecular entity and is currently in Phase II clinical trials, where it is being studied in combination with platinum doublet chemotherapy for its efficacy and safety in patients with early-stage non-small cell lung cancer[1][2][3][4]. Its chemical structure has not been fully published, but it does not appear to be associated with any previously approved drugs.

Other names: compound 121,564

Beyond the preview

Go deeper on compound 121564.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 121564.

Explore the full profile